Schwickert J, Zickgraf FM, Sprick MR. Therapy resistance on the RADar in ovarian cancer.
EMBO Mol Med 2021;
13:e14010. [PMID:
33779077 PMCID:
PMC8103092 DOI:
10.15252/emmm.202114010]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2021] [Revised: 02/10/2021] [Accepted: 02/10/2021] [Indexed: 11/21/2022] Open
Abstract
Ovarian cancer has the worst prognosis of all gynecological cancers with high‐grade serous ovarian cancer (HGSOC) accounting for the majority of ovarian cancer deaths. Therapy resistance and the selection of effective therapies for patients remains a major challenge. In this issue of EMBO Molecular Medicine, Hoppe et al present RAD51 expression as a biomarker of platinum resistance in high‐grade serous ovarian cancer (HGSOC) patients (Hoppe et al, 2021).
Collapse